Citation: Jian-Bo TONG, Xing ZHANG, Shuai BIAN, Ding LUO. Drug Design, Molecular Docking, and ADMET Prediction of CCR5 Inhibitors Based on QSAR Study[J]. Chinese Journal of Structural Chemistry, ;2022, 41(2): 220200. doi: 10.14102/j.cnki.0254-5861.2011-3268 shu

Drug Design, Molecular Docking, and ADMET Prediction of CCR5 Inhibitors Based on QSAR Study

Jian-Bo TONG ^{a, b,,} ,
Xing ZHANG ^{a, b} ,
Shuai BIAN ^{a, b} ,
Ding LUO ^{a, b}

a.
College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi'an 710021, China
b.
Shaanxi Key Laboratory of Chemical Additives for Industry, Shaanxi University of Science and Technology, Xi'an 710021, China

Corresponding author: Jian-Bo TONG, jianbotong@aliyun.com
Received Date: 27 May 2021
Accepted Date: 5 July 2021

Fund Project: Innovation Supporting Plan of Shaanxi Province—Innovation Research Team 2018TD-015the Natural Science Foundation of Shaanxi Province 2019JM-237

Figures(11)

The chemokine receptor CCR5 is a main and necessary co-receptor for which HIV can recognize and enter the cells, and has been identified as a potential new target for the design of new anti-HIV therapeutic drugs. Highly active CCR5 inhibitors can prevent HIV-1 from entering target cells and block the process of infection. In this study, HQSAR and Topomer CoMFA methods were used to establish QSAR models for 75 1-(3, 3-diphenylpropyl)-piperidinyl and urea derivatives, and cross-validation and non-cross-validation were performed on the generated models. Two models with good statistical parameters and reliable prediction capabilities are obtained: (Topomer CoMFA: q² = 0.687, r² = 0.868, r_pred² = 0.623; HQSAR: q² = 0.781, r² = 0.921, r_pred² = 0.636). Contour maps and color code maps provide a lot of useful information for determining structural requirements that affect activity. Topomer search technology was used for virtual screening and molecular design. Surfex-dock method and ADMET technology were used to conduct molecular docking, oral bioavailability and toxicity prediction of the designed drug molecules. Results showed that A/ASN425, A/GLY198 and A/TRP427 may be the potential active residues of CCR5 inhibitors evaluated in this study, with 40 newly designed 1-(3, 3-diphenylpropyl)-piperidinyl and urea derivatives which have the main ADMET properties and can be used as a reliable anti-HIV inhibitor. These results provide a certain theoretical basis for the experimental verification of new compounds in the future.
- HIV,
- CCR5 inhibitors,
- Topomer CoMFA,
- HQSAR,
- ADMET
1. [1]
  Qian, Y. J.; Wu, Z. Y.; Chen, C.; Du, K. F.; Wei, W. B. Detection of HIV-1 viral load in tears of HIV/AIDS patients. Infection 2020, 48, 929–933. doi: 10.1007/s15010-020-01508-2
2. [2]
  Gao, R.; Fang, Q. J.; Zhang, X.; Xu, Q.; Ye, H. H.; Guo, W. Y.; He, J.; Chen, Y. H.; Wang, R. X.; Wu, Z. J; Yu, J. R5 HIV-1 gp120 activates p38 MAPK to induce rat cardiomyocyte injury by the CCR5 coreceptor. Pathobiology 2019, 86, 274–284. doi: 10.1159/000502238
3. [3]
  Hemkens, L. G.; Bucher, H. C. HIV infection and cardiovascular disease. Eur. Heart. J. 2014, 35, 1373–1381. doi: 10.1093/eurheartj/eht528
4. [4]
  Moore, J. P.; Stevenson, M. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Bio. 2000, 1, 40–49. doi: 10.1038/35036060
5. [5]
  Wells, T. N. C.; Proudfoot, A. E.; Power, C. A. Chemokine receptors-the new frontier for AIDS research. Cell Chem. Biol. 1996, 3, 603−609.
6. [6]
  Palani, A.; Shapiro, S.; Clader, J. W. Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist. Bioogr. Med. Chem. Lett. 2003, 13, 705–708. doi: 10.1016/S0960-894X(02)01062-4
7. [7]
  Shahlaei, M.; Fassihi, A. QSAR analysis of some 1-(3, 3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 inhibitors using genetic algorithm-least square support vector machine. Med. Chem. Res. 2013, 22, 4384–4400. doi: 10.1007/s00044-012-0430-2
8. [8]
  Heravi, Y. E.; Sereshti, H.; Saboury, A. A. 3D QSAR studies, pharmacophore modeling, and virtual screening of diarylpyrazole-benzenesulfonamide derivatives as a template to obtain new inhibitors, using human carbonic anhydrase II as a model protein. J. Enzyme Inhib. Med. Chem. 2017, 32, 688−700. doi: 10.1080/14756366.2016.1241781
9. [9]
  Zheng, X.; He, M. X.; Tan, X.; Zheng, J.; Wang, F. Y.; Liu, S. 3D-quantitative structure-activity relationship and docking studies of coumarin derivatives as tissue kallikrein 7 inhibitors. J. Pharm. Pharmacol. 2017, 69, 1136−1144. doi: 10.1111/jphp.12751
10. [10]
  Li, S. L.; Bao, X. F.; Lu, C. H.; Ren, C. R.; Liu, G. C.; Du, H. G. Essential structural profile of novel adenosine derivatives as antiplatelet aggregation inhibitors based on 3D-QSAR analysis using CoMFA, CoMSIA, and SOMFA. Russ. J. Bioorg. Chem+. 2020, 46, 448−457. doi: 10.1134/S1068162020030103
11. [11]
  Fu, L.; Chen, Y.; Xu, C. M. 3D-QSAR, HQSAR, molecular docking, and new compound design study of 1, 3, 6-trisubstituted 1, 4-diazepan-7-ones as human KLK7 inhibitors. Med. Chem. Res. 2020, 29, 1012–1029. doi: 10.1007/s00044-020-02542-3
12. [12]
  Tong, J. B.; Shan, L.; Qin, S. S. QSAR studies of TIBO derivatives as HIV-1 reverse transcriptase inhibitors using HQSAR, CoMFA and CoMSIA. J. Mol. Struct. 2018, 1168, 56–64. doi: 10.1016/j.molstruc.2018.05.005
13. [13]
  Cheng, Y.; Mei, Z.; Tung, C. H. Studies on two types of PTP1β inhibitors for the treatment of type 2 diabetes: hologram QSAR for OBA and BBB analogues. Bioorg. Med. Chem. Lett. 2010, 20, 3329–3337. doi: 10.1016/j.bmcl.2010.04.033
14. [14]
  Castilho, M. S.; Postigo, M. P.; Montanari, C. A.; Oliva, G.; Andricopulo, A. D. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors. Bioorgan. Med. Chem. 2006, 14, 516−527. doi: 10.1016/j.bmc.2005.08.055
15. [15]
  Cumming, J. G.; Cooper, A. E.; Grime, K.; Logan, C. J.; McLaughlin, S.; Oldfield, J.; Shaw, J. S.; Tucker, H.; Winter, J.; Whittaker, D. Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3, 3-diphenylpropyl)-piperidinyl phenylacetamides. Bioorg. Med. Chem. Lett. 2005, 15, 5012–5015. doi: 10.1016/j.bmcl.2005.08.014
16. [16]
  Burrows, J. N.; Cumming, J. G.; Fillery, S. M.; Hamlin, G. A.; Hudson, J. A.; Jackson, R. J.; McLaughlin, S.; Shaw, J. S. Modulators of the human CCR5 receptor. Part 1: discovery and initial SAR of 1-(3, 3-diphenylpropyl)-piperidinyl amides and ureas. Bioorg. Med. Chem. Lett. 2005, 15, 25–28. doi: 10.1016/j.bmcl.2004.10.044
17. [17]
  Niu, B.; Lu, Y.; Wang, J. Y.; Hu, Y.; Chen, J. H.; Chen, Q.; He, G. W.; Zheng, L. F. 2D-SAR, Topomer CoMFA and molecular docking studies on avian influenza neuraminidase inhibitors. Comput. Struct. Biotec. 2019, 17, 39–48. doi: 10.1016/j.csbj.2018.11.007
18. [18]
  Zhu, W. L.; Chen, G.; Hu, L. H.; Luo, X. M.; Gui, C. S.; Luo, C.; Puah, C. M.; Chem, K. X.; Jiang, H. L. QSAR analyses on ginkgolides and their analogues using CoMFA, CoMSIA, and HQSAR. Bioorg. Med. Chem. 2005, 13, 313−322. doi: 10.1016/j.bmc.2004.10.027
19. [19]
  Huang, D. D.; Liu, Y. L.; Shi, B. Z.; Li, Y. T.; Wang, G. X.; Liang, G. Z. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking. J. Mol. Graph. Model. 2013, 45, 65−83. doi: 10.1016/j.jmgm.2013.08.003
20. [20]
  Shirmohammadi, M.; Mohammadinasab, E.; Bayat, Z. Prediction of lipophilicity of some quinolone derivatives by using quantitative structure-activity relationship. Curr. Drug. Discov. Technol. 2021, 18, 83–94. doi: 10.2174/1570163816666191108145026
21. [21]
  Xiang, Y. H.; Hou, Z. Y.; Zhang, Z. Y. Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors. Chem. Biol. Drug Des. 2012, 79, 760–770. doi: 10.1111/j.1747-0285.2012.01341.x
22. [22]
  Kiralj, R.; Ferreira, M. Basic validation procedures for regression models in QSAR and QSPR studies: theory and application. J. Brazil. Chem. Soc. 2009, 20, 770–787. doi: 10.1590/S0103-50532009000400021
23. [23]
  Aynur, O. A.; Nina, G. J.; Terry, W. S.; Mark, T. D. C. The better predictive model: high q² for the training set or low root mean square error of prediction for the test set? Mol. Inform. 2010, 24, 385–396.
24. [24]
  Golbraikh, A.; Tropsha, A. Beware of q²! J. Mol. Graph. Model. 2002, 20, 269–276. doi: 10.1016/S1093-3263(01)00123-1
25. [25]
  Sterling, T.; Irwin, J. J. ZINC 15-ligand discovery for everyone. J. Chem. Inf. Model. 2015, 55, 2324-2337. doi: 10.1021/acs.jcim.5b00559
26. [26]
  Tripathi, A.; Bankaitis, V. A. Molecular docking: from lock and key to combination lock. J. Mol. Med. Clin. App. 2017, 2, 1–9. doi: 10.1016/j.nhccr.2017.03.001
27. [27]
  Dudutiene, V.; Zubriene, A.; Kairys, V.; Smirnov, A.; Smirnoviene, J.; Leitans, J.; Kazaks, A.; Tars, K.; Manakova, L.; Grazulis, S.; Matulis, D. Isoform-selective enzyme inhibitors by exploring pocket size according to the lock-and-key Principle. Biophys. J. 2020, 119, 1513–1524. doi: 10.1016/j.bpj.2020.08.037
28. [28]
  Liu, J.; Li, Y.; Zhang, H. X.; Zhang, S. W.; Yang, L. Studies of H4R antagonists using 3D-QSAR, molecular docking and molecular dynamics. J. Mol. Model. 2012, 18, 991–1001. doi: 10.1007/s00894-011-1137-x
29. [29]
  Cleves, A. E.; Jain, A. N. Knowledge-guided docking: accurate prospective prediction of bound configurations of novel ligands using Surfex-Dock. J. Comput. Aided. Mol. Des. 2015, 29, 485–509. doi: 10.1007/s10822-015-9846-3
30. [30]
  Tong, J. B.; Luo, D.; Bian, S.; Zhang, X. Structural investigation of tetrahydropteridin analogues as selective PLK1 inhibitors for treating cancer through combined QSAR techniques, molecular docking, and molecular dynamics simulations. J. Mol. Liq. 2021, 335, 116235–17. doi: 10.1016/j.molliq.2021.116235
31. [31]
  Zhang, X. Z.; Xu, Y.; Jian, M. M.; Yang, K.; Ma, Z. Y. Synthesis, in vitro assays, molecular docking, theoretical ADMET prediction, and evaluation of 4-methoxy-phenylthiazole-2-amine derivatives as acetylcholinesterase inhibitors. Med. Chem. Res. 2019, 28, 1683–1693. doi: 10.1007/s00044-019-02405-6
32. [32]
  Jain, A. N. Surfex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput. Aided. Mol. Des. 2007, 21, 281–306. doi: 10.1007/s10822-007-9114-2
1. [1]
  Yin-Xiang Zhang , Christophe Pannecouque , Erik De Clercq , Enzo Tramontano , Angela Corona , Laura Dettori , Phuong-Thao Tran , Xu-Dong Li , Shuo Su , Shuai Wang , Fen-Er Chen . Discovery of novel and potent non-nucleoside reverse transcriptase inhibitors through structure-based drug design for HIV treatment. Chinese Chemical Letters, 2026, 37(8): 112448-. doi: 10.1016/j.cclet.2026.112448
2. [2]
  Bairu Meng , Zongji Zhuo , Han Yu , Sining Tao , Zixuan Chen , Erik De Clercq , Christophe Pannecouque , Dongwei Kang , Peng Zhan , Xinyong Liu . Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3-d]pyrimidine derivatives as novel HIV-1 NNRTIs. Chinese Chemical Letters, 2024, 35(6): 108827-. doi: 10.1016/j.cclet.2023.108827
3. [3]
  Xiaojia Xue , Xiangyi Jiang , Jiaojiao Dai , Xinyong Liu , Eline Pellaers , Debyser Zeger , Peng Zhan . Deciphering the HIV reservoir: From epigenetic regulators to RNA-mediated regulation. Chinese Chemical Letters, 2026, 37(6): 112019-. doi: 10.1016/j.cclet.2025.112019
4. [4]
  Kai Tang , Guochao Wei , Peng Zhan . Breaking the impossible: The evolutionary journey of lenacapavir, a long-acting anti-HIV drug. Chinese Chemical Letters, 2025, 36(7): 110500-. doi: 10.1016/j.cclet.2024.110500
5. [5]
  Deyan Wu , Qingjiang Ma , Yanquan Chen , Guofeng Yang , Fengcai Zhang , Meiyan Jiang , Xue Wang , Xingfu Liu , Qian Zhou , Yi-You Huang , Zhe Li , Hai-Bin Luo . Plasma metabolites-based drug design: Discovery of novel and highly selective phosphodiesterase 5 inhibitors. Chinese Chemical Letters, 2026, 37(5): 111236-. doi: 10.1016/j.cclet.2025.111236
6. [6]
  Xueyi Weng , Weiyan Li , Haipeng Tan , Zhiqing Pang , Jinfeng Gao , Shiteng Cai , Jing Chen , Qiaozi Wang , Qiyu Li , Youran Li , Hongbo Yang , Zhengmin Wang , Yiwen Tan , Yuyuan Fu , Chengzhi Han , Zheyong Huang , Yanan Song , Junbo Ge , Juying Qian . Engineered macrophage membrane fusion liposomes carrying siRNA for spatiotemporal regulation of the CCL2/CCR2 axis for cardiac repair. Chinese Chemical Letters, 2026, 37(7): 111666-. doi: 10.1016/j.cclet.2025.111666
7. [7]
  Wenfeng Shao , Chuanlin Li , Chenggang Wang , Guangsen Du , Shunshun Zhao , Guangmeng Qu , Yupeng Xing , Tianshuo Guo , Hongfei Li , Xijin Xu . Stabilization of zinc anode by trace organic corrosion inhibitors for long lifespan. Chinese Chemical Letters, 2025, 36(3): 109531-. doi: 10.1016/j.cclet.2024.109531
8. [8]
  Lu-Lu He , Lan-Tu Xiong , Xin Wang , Yu-Zhen Li , Jia-Bao Li , Yu Shi , Xin Deng , Zi-Ning Cui . Application of inhibitors targeting the type III secretion system in phytopathogenic bacteria. Chinese Chemical Letters, 2025, 36(4): 110044-. doi: 10.1016/j.cclet.2024.110044
9. [9]
  Muhammad Nafees , Muhammad Hanif , Piaoping Yang . Metallodrugs: From mere cytotoxic agents to immune modulators and checkpoint inhibitors. Chinese Chemical Letters, 2026, 37(4): 111013-. doi: 10.1016/j.cclet.2025.111013
10. [10]
  Aimin Fu , Chunmei Chen , Qin Li , Nanjin Ding , Jiaxin Dong , Yu Chen , Mengsha Wei , Weiguang Sun , Hucheng Zhu , Yonghui Zhang . Niduenes A−F, six functionalized sesterterpenoids with a pentacyclic 5/5/5/5/6 skeleton from endophytic fungus Aspergillus nidulans. Chinese Chemical Letters, 2024, 35(9): 109100-. doi: 10.1016/j.cclet.2023.109100
11. [11]
  Shiqi Xu , Zi Ye , Shuang Shang , Fengge Wang , Huan Zhang , Lianguo Chen , Hao Lin , Chen Chen , Fang Hua , Chong-Jing Zhang . Pairs of thiol-substituted 1,2,4-triazole-based isomeric covalent inhibitors with tunable reactivity and selectivity. Chinese Chemical Letters, 2024, 35(7): 109034-. doi: 10.1016/j.cclet.2023.109034
12. [12]
  Mianling Yang , Meehyein Kim , Peng Zhan . Modular miniaturized synthesis and in situ biological evaluation facilitate rapid discovery of potent MraY inhibitors as antibacterial agents. Chinese Chemical Letters, 2025, 36(2): 110455-. doi: 10.1016/j.cclet.2024.110455
13. [13]
  Chunyu Yan , Qinglong Qiao , Wei Zhou , Xuelian Zhou , Yonghui Chen , Lu Miao , Zhaochao Xu . FRET-based in vitro assay for rapid detecting of SARS-CoV-2 entry inhibitors. Chinese Chemical Letters, 2025, 36(5): 110258-. doi: 10.1016/j.cclet.2024.110258
14. [14]
  Zhaoyong Kang , Shen Li , Yan Li , Jingfeng Song , Yangrui Peng , Yihua Chen . Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024). Chinese Chemical Letters, 2025, 36(7): 110447-. doi: 10.1016/j.cclet.2024.110447
15. [15]
  Yi-You Huang , Xiang Luo , Kai Zhang , Yulan Liang , Furong Zhang , Guochao Liao , Shenghong Xie , Pei-Luo Huang , Siyu Hou , Qian Zhou , Yong Zou , Hai-Bin Luo . Structure-based optimization of isoaurostatin as novel PDE4 inhibitors with anti-fibrotic effects. Chinese Chemical Letters, 2025, 36(8): 110586-. doi: 10.1016/j.cclet.2024.110586
16. [16]
  Yifan Feng , Chengjuan Chen , Anqi Shao , Qingyang Zhang , Lan Sun , Hai-Yu Hu , Tiantai Zhang . Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs. Chinese Chemical Letters, 2025, 36(12): 110963-. doi: 10.1016/j.cclet.2025.110963
17. [17]
  Linan Wu , Shenghua Gao , Peng Zhan . Breakthrough progress in the structural determination of the monkeypox virus I7L protease and the design of targeted inhibitors. Chinese Chemical Letters, 2026, 37(4): 111845-. doi: 10.1016/j.cclet.2025.111845
18. [18]
  Huijuan Luo , Haiyue Zuo , Jianzhong Zhu , Juanjuan Zhao , Roufen Chen , Xinle Yang , Fangqi Cao , Ruohan Lou , Xiaowu Dong , Yangyang Bian , Ligen Lin . Computer-aided discovery of peptidyl arginine deiminase 4 inhibitors to suppress NETosis and accelerate diabetic wound healing. Chinese Chemical Letters, 2026, 37(6): 111510-. doi: 10.1016/j.cclet.2025.111510
19. [19]
  Jian Song , Shenghui Wang , Qiuge Liu , Xiao Wang , Shuo Yuan , Hongmin Liu , Saiyang Zhang . N-Benzyl arylamide derivatives as novel and potent tubulin polymerization inhibitors against gastric cancers: Design, structure–activity relationships and biological evaluations. Chinese Chemical Letters, 2025, 36(2): 109678-. doi: 10.1016/j.cclet.2024.109678
20. [20]
  Han Yuan , Fengcai Zhang , Hongzhe Huang , Jiafei Wu , Yi Yang , Wanyi Huang , Dongjing Yang , Zhuoming Li , Zhe Li , Ling Huang , Yi-You Huang , Hai-Bin Luo , Lei Guo . Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy. Chinese Chemical Letters, 2025, 36(4): 109965-. doi: 10.1016/j.cclet.2024.109965

Get Citation

PDF

XML

Metrics

PDF Downloads(2)
Abstract views(2104)
HTML views(95)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142